MGL DIP - Annual Results 2019 SupplementSource: RNS
Publication of Prospectus Supplement and 2019 Annual Financial Report
The following prospectus supplement (the Supplement) has been approved by the Financial Conduct Authority and is available for viewing:
Macquarie Group Limited (MGL) Supplement dated 3 May 2019 to the Offering Memorandum dated 13 June 2018 (the Offering Memorandum) in respect of the Debt Instrument Programme
To view the full document, please paste the following URL into the address bar of your browser.
In addition, MGL has published a copy of the MGL 2019 Annual Financial Report on the Macquarie website at http://www.macquarie.com
To view the full document, please paste the following URL into the address bar of your browser:
A copy of the Supplement and the MGL 2019 Annual Financial Report have also been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
For further information, please contact:
Macquarie Group Limited
Mr. Angus Cameron
Level 6, 50 Martin Place
Telephone : +61 2 8232 3333
Fax : +61 2 8232 4227
DISCLAIMER ‑ INTENDED ADDRESSEES
Please note that the information contained in the Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Offering Memorandum) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Offering Memorandum, as supplemented, is not addressed. Prior to relying on the information contained in the Offering Memorandum, as supplemented, you must ascertain from the Offering Memorandum, as supplemented, whether or not you are part of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above requirement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.